Literature DB >> 25981171

Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia.

Dibyadeep Datta1, Dominique Arion2, John P Corradi3, David A Lewis4.   

Abstract

BACKGROUND: Cognitive dysfunction in schizophrenia is associated with a lower density of dendritic spines on deep layer 3 pyramidal cells in the dorsolateral prefrontal cortex (DLPFC). These alterations appear to reflect dysregulation of the actin cytoskeleton required for spine formation and maintenance. Consistent with this idea, altered expression of genes in the cell division cycle 42 (CDC42)-CDC42 effector protein (CDC42EP) signaling pathway, a key organizer of the actin cytoskeleton, was previously reported in DLPFC gray matter from subjects with schizophrenia. We examined the integrity of the CDC42-p21-activated serine/threonine protein kinases (PAK)-LIM domain-containing serine/threonine protein kinases (LIMK) signaling pathway in schizophrenia in a layer-specific and cell type-specific fashion in DLPFC deep layer 3.
METHODS: Using laser microdissection, samples of DLPFC deep layer 3 were collected from 56 matched pairs of subjects with schizophrenia and comparison subjects, and levels of CDC42-PAK-LIMK pathway messenger RNAs were measured by quantitative polymerase chain reaction. These same transcripts also were quantified by microarray in samples of individually microdissected deep layer 3 pyramidal cells from a subset of the same subjects and from monkeys exposed to antipsychotics.
RESULTS: Relative to comparison subjects, CDC42EP4, LIMK1, LIMK2, ARHGDIA, and PAK3 messenger RNA levels were significantly upregulated in subjects with schizophrenia in laminar and cellular samples. In contrast, CDC42 and PAK1 messenger RNA levels were significantly downregulated specifically in deep layer 3 pyramidal cells. These differences were not attributable to psychotropic medications or other comorbid factors.
CONCLUSIONS: Findings from the present and prior studies converge on synergistic alterations in CDC42 signaling pathway that could destabilize actin dynamics and produce spine deficits preferentially in deep layer 3 pyramidal cells in schizophrenia.
Copyright © 2015 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Actin cytoskeleton; CDC42; Dendritic spine; Prefrontal cortex; Schizophrenia; mRNA

Mesh:

Substances:

Year:  2015        PMID: 25981171      PMCID: PMC4600637          DOI: 10.1016/j.biopsych.2015.03.030

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  76 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

2.  The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys.

Authors:  Karl-Anton Dorph-Petersen; Joseph N Pierri; James M Perel; Zhuoxin Sun; Allan R Sampson; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2005-09       Impact factor: 7.853

3.  Developmental Expression Patterns of GABAA Receptor Subunits in Layer 3 and 5 Pyramidal Cells of Monkey Prefrontal Cortex.

Authors:  Dibyadeep Datta; Dominique Arion; David A Lewis
Journal:  Cereb Cortex       Date:  2014-03-07       Impact factor: 5.357

4.  Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder.

Authors:  Glenn T Konopaske; Nicholas Lange; Joseph T Coyle; Francine M Benes
Journal:  JAMA Psychiatry       Date:  2014-12-01       Impact factor: 21.596

5.  Altered cortical CDC42 signaling pathways in schizophrenia: implications for dendritic spine deficits.

Authors:  Masayuki Ide; David A Lewis
Journal:  Biol Psychiatry       Date:  2010-04-10       Impact factor: 13.382

6.  Reduced pyramidal cell somal volume in auditory association cortex of subjects with schizophrenia.

Authors:  Robert A Sweet; Joseph N Pierri; Sungyoung Auh; Allan R Sampson; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2002-12-03       Impact factor: 7.853

Review 7.  Dendritic spine pathology in schizophrenia.

Authors:  J R Glausier; D A Lewis
Journal:  Neuroscience       Date:  2012-04-27       Impact factor: 3.590

8.  Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia.

Authors:  T Hashimoto; D Arion; T Unger; J G Maldonado-Avilés; H M Morris; D W Volk; K Mirnics; D A Lewis
Journal:  Mol Psychiatry       Date:  2007-05-01       Impact factor: 15.992

9.  Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia.

Authors:  Takanori Hashimoto; H Holly Bazmi; Karoly Mirnics; Qiang Wu; Allan R Sampson; David A Lewis
Journal:  Am J Psychiatry       Date:  2008-02-15       Impact factor: 18.112

10.  Altered gene expression in the dorsolateral prefrontal cortex of individuals with schizophrenia.

Authors:  A L Guillozet-Bongaarts; T M Hyde; R A Dalley; M J Hawrylycz; A Henry; P R Hof; J Hohmann; A R Jones; C L Kuan; J Royall; E Shen; B Swanson; H Zeng; J E Kleinman
Journal:  Mol Psychiatry       Date:  2013-03-26       Impact factor: 15.992

View more
  49 in total

1.  Laser capture microdissection-targeted mass spectrometry: a method for multiplexed protein quantification within individual layers of the cerebral cortex.

Authors:  Matthew L MacDonald; Daley Favo; Megan Garver; Zhe Sun; Dominique Arion; Ying Ding; Nathan Yates; Robert A Sweet; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2018-11-02       Impact factor: 7.853

2.  Transcriptome Alterations in Prefrontal Pyramidal Cells Distinguish Schizophrenia From Bipolar and Major Depressive Disorders.

Authors:  Dominique Arion; Zhiguang Huo; John F Enwright; John P Corradi; George Tseng; David A Lewis
Journal:  Biol Psychiatry       Date:  2017-04-04       Impact factor: 13.382

3.  Language Impairment with a Partial Duplication of DOCK8.

Authors:  Antonio Benítez-Burraco; Maite Fernández-Urquiza; Mª Salud Jiménez-Romero
Journal:  Mol Syndromol       Date:  2020-12-11

4.  Genetic variation in the 3'-untranslated region of PAK1 influences schizophrenia susceptibility.

Authors:  Juan Jiang; Jianxiong Long; Weijun Ling; Guifeng Huang; Li Su
Journal:  Exp Ther Med       Date:  2017-01-12       Impact factor: 2.447

Review 5.  Mapping the Consequences of Impaired Synaptic Plasticity in Schizophrenia through Development: An Integrative Model for Diverse Clinical Features.

Authors:  Jennifer K Forsyth; David A Lewis
Journal:  Trends Cogn Sci       Date:  2017-07-25       Impact factor: 20.229

Review 6.  Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia.

Authors:  David W Volk
Journal:  Neurobiol Dis       Date:  2016-12-19       Impact factor: 5.996

7.  Dysbindin-1 contributes to prefrontal cortical dendritic arbor pathology in schizophrenia.

Authors:  Glenn T Konopaske; Darrick T Balu; Kendall T Presti; Grace Chan; Francine M Benes; Joseph T Coyle
Journal:  Schizophr Res       Date:  2018-05-11       Impact factor: 4.939

8.  Altered Expression of ARP2/3 Complex Signaling Pathway Genes in Prefrontal Layer 3 Pyramidal Cells in Schizophrenia.

Authors:  Dibyadeep Datta; Dominique Arion; Kaitlyn M Roman; David W Volk; David A Lewis
Journal:  Am J Psychiatry       Date:  2016-08-13       Impact factor: 18.112

Review 9.  Layer 3 Excitatory and Inhibitory Circuitry in the Prefrontal Cortex: Developmental Trajectories and Alterations in Schizophrenia.

Authors:  Gil D Hoftman; Dibyadeep Datta; David A Lewis
Journal:  Biol Psychiatry       Date:  2016-06-04       Impact factor: 13.382

10.  Functional analysis of rare variants found in schizophrenia implicates a critical role for GIT1-PAK3 signaling in neuroplasticity.

Authors:  M J Kim; J Biag; D M Fass; M C Lewis; Q Zhang; M Fleishman; S P Gangwar; M Machius; M Fromer; S M Purcell; S A McCarroll; G Rudenko; R T Premont; E M Scolnick; S J Haggarty
Journal:  Mol Psychiatry       Date:  2016-07-26       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.